Lung Cancer Clinical Trial

Assessing the Integration of Tobacco Cessation Treatment Into Lung Cancer Screening (LCS)

Summary

This randomized controlled trial seeks to evaluate the effectiveness of alternative strategies to integrate smoking cessation interventions into the delivery of low-dose CT (LDCT) lung cancer screening. Using a factorial design, current smokers who enroll will be randomly assigned to receive these interventions: (1) smoking cessation counseling support by telephone or videoconferencing (short duration vs. long duration); (2) nicotine patch treatment (NRT) (short vs.long duration); (3) counselor-facilitated referral (vs. no referral) to an online resource to connect smokers to a community-based social service resources.

View Full Description

Full Description

Evidence-based tobacco dependence treatment consists of behavioral counseling and pharmacotherapy. Nicotine patch is an FDA-approved cessation aid. The optimal duration of counseling and pharmacotherapy for patients undergoing low-dose CT (LDCT) lung screening is not clear. In addition, helping smokers to address other social and psychological barriers might help them succeed in quitting smoking. This randomized controlled trial will test, in a factorial design, two options for delivering each of 3 interventions to help current smokers stop smoking in the context of having routine CT lung cancer screening. Patients will receive 4 or 8 weeks of behavioral counseling (with their choice of video conferencing or regular telephone calls), 2 or 8 weeks of nicotine patch, and will receive referral (vs. no referral) to an online resource to connect smokers to community-based social service resources. Outcome measures for smoking cessation will be assessed by a survey administered by phone at 3,and 6 months.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Scheduled to undergo LDCT-LCS at a participating Mass General Brigham Health Care System LCS site
Speak English or Spanish.
Current smokers: smoked a cigarette, even a puff, in the last 30 days.
Medicare coverage requirement (age 50-80 years, 20+ pack/years).
Residing within the USA.

Exclusion Criteria:

Undergoing lung CT as part of a diagnostic or abnormal follow-up evaluation.
Unable to give informed consent due to psychiatric or cognitive impairment as determined in consultation with study PI or treating clinician.
No access to a telephone or cannot communicate by telephone.

Study is for people with:

Lung Cancer

Phase:

Phase 4

Estimated Enrollment:

640

Study ID:

NCT03611881

Recruitment Status:

Recruiting

Sponsor:

Massachusetts General Hospital

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 6 Locations for this study

See Locations Near You

Massachusetts General Hospital
Boston Massachusetts, 02114, United States More Info
Elyse R Park, PhD
Contact
Brigham & Women's Hospital
Boston Massachusetts, 02115, United States More Info
Jessica Lorusso
Contact
Brigham & Women's Faulkner Hospital
Boston Massachusetts, 02130, United States More Info
Jennifer Haas, MD
Contact
Newton-Wellesley Hospital
Newton Massachusetts, 02462, United States More Info
Anand Prabhakar, MD
Contact
Martha's Vineyard Hospital
Oak Bluffs Massachusetts, 02557, United States More Info
Pieter Pil, MD, PhD
Contact
Salem Hospital
Salem Massachusetts, 01970, United States More Info
Amie Samuylov
Contact

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 4

Estimated Enrollment:

640

Study ID:

NCT03611881

Recruitment Status:

Recruiting

Sponsor:


Massachusetts General Hospital

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider